Clinical news

Clinical operations as a beat of its own: monitoring, data management, sites and sponsors. Nothing else on this list covers the work most clinical staff actually do.

Breaking news with the context attached: funding, trials and deals, written for people who work in the industry.

CMC, formulation and analytics: the daily subject of the roles nobody else writes about.

Industry news with an unusually strong careers desk, so it covers hiring and layoffs as a subject rather than as an aside.

Biopharma, regulatory, clinical and financing in one wire, with unusually complete deal coverage.

Trial operations and the CRO industry, which is a large share of European hiring and thinly covered elsewhere.

Delivery platforms, devices and the companies building them, which is where a lot of the formulation hiring sits.

Preclinical pipelines and the tooling around them, including where machine learning has actually landed.

Broad daily coverage across biotech, with strong reporting on layoffs and site closures.

Big pharma: approvals, commercialisation and manufacturing, which is where most of the jobs are.

Omics, gene editing and bioprocessing: the techniques our bench and process listings ask for by name.

Diagnostics, companion tests and the clinical end of omics. A sister title to GEN, so the duplicate rule in News::IngestFeedService is what keeps one story to one card.

Funding, startups and IPOs at the healthcare end, narrowed to the biopharma desk.

Device engineering and the contract manufacturers behind it, written for the engineers rather than about them.

Devices and diagnostics. Adjacent to biotech and a real part of the same labour market.

Market access, commercialisation and supply chain, which is the half of the industry the science press skips.

The commercial side: launch, pricing and market access. Nothing else here covers the half of the industry that decides whether a drug reaches anybody.

Plants, fill-finish and capacity announcements. A new line somewhere is a hiring plan somewhere, usually a quarter ahead of the adverts.

Manufacturing and development, including the automation work that is changing what a process role looks like.

British pharma business, short and daily. Thin on analysis and useful for the deals the larger titles skip.

Commercial and medical affairs coverage, a part of the industry the others under-serve.

Leadership and strategy. Useful for the moves and reorganisations that precede hiring.

Original reporting on biotech, trials, the FDA and policy. Slower than the wires, and usually the version that holds up.

Techbio and synthetic biology from the venture side, which reaches companies before the trade press does.

Methods and techniques rather than business: assays, metabolomics, instrumentation. The bench half of what the trade press reports as deals.

Systems and computational biology, in press rather than published, so it arrives before the journal issue does.

Medicinal chemistry and manufacturing from the chemistry side, which is where a lot of our listings actually sit.

British genomics coverage with a sequencing and computational bias, which is the angle the general trade press reaches last.

Derek Lowe reading the drug discovery literature in public. One person, and the most useful judgement in the field.

Devices, delivery and diagnostics as engineering. The academic end of what MedTech Dive reports as business.

Peer-reviewed methods and platform advances, ahead of the trade press by months.

Where a trial result becomes evidence rather than a press release, months before the trade press treats it as settled.

Reviews rather than primary papers, which is the right grain for a reader deciding whether a field is worth retraining into.

Where modality and approval trends are argued out before the trade press reports them as facts.

Open access, so every story on this row links to something a reader can actually read. The only publisher here of which that is true.

Dan Erlanson and Teddy Zartler on fragment-based drug discovery, since 2008 and still weekly. Narrow on purpose: it is read by the people who do this for a living.

The AAAS newsroom rather than the journal: research policy, funding and misconduct, which move careers more than any single paper does.

Where genomic epidemiologists post an outbreak analysis before a preprint exists. It is a Discourse forum, so the feed carries thread activity rather than finished articles: the highest signal here and the least tidy.

Valentine Svensson on the statistics of single-cell RNA sequencing. Dense, quantitative and the reason this row is under journals rather than under commentary.

Policy and biosecurity from the industry association. Read as a position rather than as reporting.

Primary source. Approvals and guidance straight from the agency, not summarised.

The European trade body for small and mid-sized health technology companies, which is exactly the employer this board serves. Read as a position, like Bio.News, and it is the only source here covering EU policy from that side.

Hyman, Phelps and McNamara on orphan drugs, biosimilars and exclusivity, in more detail than anybody else bothers with.

Primary source for US decisions, which drive hiring in regulatory affairs everywhere.

A monthly account of what the pandemic preparedness and biosecurity organisations are actually doing, which is where a surprising number of computational roles sit.

The third regulator beside the FDA and the EMA. Since Brexit a British approval is its own event, and this is the agency publishing it rather than somebody reporting it.

Biotech and pharma IP. A patent decision reshapes a pipeline, and therefore a hiring plan, years ahead.

Technically grounded essays on AI and biological risk. Here with Bio.News because biosecurity is policy, and like Bio.News it is a position rather than reporting.

Europe's flagship molecular biology laboratory, heavily computational across EMBL-EBI, imaging and structural biology, and a major employer in six countries. Its own Workday link is the lab hiring for itself, which is the EMA and FDA precedent rather than a jobs board.

Continental biotech business in English, covering the German, Swiss and Nordic companies the English-language trade press reaches late.

The best single source on the European biotech scene, and on the clusters we hire into.

Strategy, partnering and investment. Funding rounds are the leading indicator of hiring.

Atlas Venture writing about company building and biotech economics from inside the cap table.

Flagship Pioneering writing about the companies it builds. Carried for the same reason as LifeSciVC and read the same way: this is a shareholder describing its own portfolio.

Quarterly, with a five item archive. The smallest row on this list and carried because its subject is the intersection this category exists for.

Long-form essays on engineered biology, editorially independent of the company whose name it carries. The best writing in this category and the one to read if you only read one.

Shelby Newsad on how science gets funded and how biological data gets priced, which is the commercial question under every techbio story.

A few posts a year on scientific autonomy, spatial biology and therapeutic strategy. Quiet enough that it is here for the pieces rather than the feed.

Independent commentary, carried as a second opinion against the trade press above rather than as a source of facts.

Lior Pachter on single-cell methods, quantification and research integrity. Confrontational and usually right, which is why it is worth the low volume.

Lab automation and agents in the lab, written seriously rather than as vendor copy. The only source found on this subject that is not a supplier's blog, and it posts rarely.

Computational biology and machine learning applied to drug discovery, written by people building it rather than reporting on it.

Eric Topol on AI and medicine: long, evidence-led and consistently ahead of the trade press on what the models can actually do.

An independent weekly read on biotech with a computational slant, written by one person with no employer to please.

Weekly European coverage of AI in drug discovery, which is the cadence Decoding Bio and Owl Posting do not have.

Monthly long-form on how a scientific breakthrough reshapes an industry. A small archive and good writing.

Keith Robison on sequencing technology, taking instrument chemistry and vendor claims apart in a way no trade publication attempts. Several posts a month.

Essays on where AI in biology has and has not worked. One person and a post a month, so it is here for the quality and not the cadence.

Stephen Turner rounding up genomics methods, tools and papers weekly. One of the few individual feeds in this field with a real cadence.

Quantitative essays on biotech and metascience by a mathematician who reads the primary literature. Independent of every interest this industry has.

Jesse Johnson on how software, automation and data actually get adopted inside a biotech organisation, which is a different question from whether the methods work. Weekly.

Elliot Hershberg on the companies and ideas at the frontier of biology. Infrequent, which is stated here rather than discovered later: the newest post when this row was added was three months old.

Paul Knoepfler on stem cells and cell therapy, including the unproven-clinic trade nobody else names. A working scientist writing under his own name about an industry that would rather he did not.

A weekly digest of cheminformatics papers, preprints and tool releases. A feeder for the primary literature we deliberately do not carry.

One genomics result or method per post, unpacked properly. Roughly monthly despite the name.

A weekly round-up of where machine learning is actually landing in drug discovery, with the deals attached. The cadence Decoding Bio and Owl Posting do not have.

The trade from a European regulatory angle, which is the part of agricultural biotech that moves fastest and matters most here.

Crop protection and biologicals, including the product approvals that decide what gets developed next.

Plant breeding and seed policy in Europe, including gene editing law. High volume, so it is the one to stop reading first if the column gets crowded.

Where agriculture meets sensing, data and automation. The same engineering that turns up in bioprocess roles, one industry along.

The trade paper for biomanufacturing: process development, scale-up, single-use and facility build-outs. The feed at /feed is dead and /rss.xml is the live one.

Outsourced development and manufacturing, which is the half of the industry that hires without ever owning a molecule. Roughly weekly, so it is here for the subject rather than the cadence.

A for-profit research organisation publishing its work directly as web-native pubs, negative results included. The highest volume row on this list at 125 items, so it is the first to watch if the column floods.

The Oxford Protein Informatics Group writing weekly about antibody modelling and protein machine learning. It posts its own group vacancies in a blog category, which is a lab advertising its own openings rather than a jobs board.

AI for biology from the Biohub network: protein modelling, cell imaging, the virtual cell. An institutional voice, but it describes results rather than ambitions.

The EMBL-EBI team behind ChEMBL on releases, schema changes and chemical data curation. European, public, and the canonical source for anybody building on it.

Short essays on simulation, computational chemistry and building a scientific software company from somebody doing both.

Protein design machine learning from a Delft and Zurich company, with real method write-ups. **The feed address is not Cradle's**: their site exposes none, so this is generated by a third party and will break one day with nobody to tell us.

Fifteen years of worked bioinformatics walkthroughs. Reference material rather than news, and carried because a reader who follows one of these links learns something.

A bioinformatics consultancy writing honestly about what works in production rather than what demos well. A company blog that earns its place, which most do not.

The author of BWA, minimap2 and samtools on algorithms and data formats. Quarterly at best, and here for the same reason Owl Posting is: nobody else can write these posts.

The centre of gravity of computational protein design, and the institute whose spinouts hire across this field. The Baker Lab's own feed fails TLS certificate validation, so this is the one address worth reading.

A working computational chemist posting short runnable RDKit and PyTorch notebooks, several times a month. No press releases, ever.

The Jean Fan lab at Johns Hopkins on spatial transcriptomics, plus unusually candid posts on running a computational group.

The strongest engineering blog of any company in this field: agent benchmarks for biological analysis, continuous benchmarking, biosecurity engineering. Almost no marketing, which is rare enough to be the reason it is here.

Chris Swain on scientific computing for chemists: scripts, tooling and language-model experiments. The apex host, because www.macinchem.org redirects.

Peter Kenny arguing, at length and in public, that the field's methods do not measure what they claim to. Adversarial by design and the counterweight to every other row in this category.

Real-time pathogen phylogenetics tooling. Software and biology in the same post, which is the whole reason this category exists.

The Nextflow pipeline community: releases, maintainer notes and workflow engineering practice. As close as this field gets to a trade paper for bioinformatics engineers.

Target identification as data science, from the EMBL-EBI, GSK, Sanofi and Genentech consortium. Genetics to drug, with the methodology published.

The pre-competitive consortium for life science R&D data standards: FAIR data, lab data architecture, preclinical submission. Software inside pharma, and covered essentially nowhere else.

Pat Walters benchmarking machine learning for small-molecule discovery rather than announcing it. The feed carries whole posts and runs to 4.3 MB, which is inside Core::FetchUrlService::MAX_BYTES and the largest thing on this list.

Greg Landrum on the toolkit most of cheminformatics is built on. Reproducible posts on fingerprints, conformers and performance, from the person who wrote it.

Long-read assembly benchmarking from the author of Unicycler and Trycycler. Methodical and test-driven, which is rarer in this field than it should be.

Scanpy, AnnData and the single-cell Python ecosystem: releases and design decisions. Quiet, and its newest post was three months old when this row was added.